-
Join 92 other subscribers
-
Recent Posts
Top Rated
Most Popular:
Blogroll
Conferences
Intellectual Property
Journals
MedChem Resources
News
Organic Chemistry Resources
- Abbott
- adverse events
- allosteric
- allosteric inhibitor
- amine basicity
- Analgesic
- animal PK
- anti-viral
- AstraZeneca
- Aurora
- beta-secretase
- bioactivation
- BIRB-796
- Boehringer Ingelheim
- cancer
- cardiotoxicity
- cellular potency
- CGRP
- chloro
- CNS penetration
- computational method
- crystal packing
- CYP450
- Deuterium
- Doramapimod
- FAAH
- Fatty acid amide hydrolase
- fluorine
- free drug
- functional antagonist
- Gly-T1
- gpcr
- hepatotoxicity
- hERG
- immunosuppressant
- isostere
- kinase
- kinetic isotope effect
- Lexicon Pharmaceuticals
- LipE
- Merck
- metabolism
- mTOR
- nitrile
- Novartis
- osteoarthritis
- P-gp
- p38
- Pain
- PF-04457845
- PF-3845
- Pfizer
- Phase I
- Phase II
- Phase III
- POC
- PPB
- protein binding
- PSA
- reactive metabolite
- review
- RG1678
- rheumatoid arthritis
- Roche
- S1P1
- S1PL
- Schizophrenia
- solubility
- Structural alert
- Structure Based Design
- switch pocket
- synthesis
- toxicity
- Transporters
- X-ray data
Categories
Category Archives: Transporter Modulator
The Discovery of RG1678 (Gly-T1 inhibitor)
In this interesting J.Med.Chem. article workers from Roche describe the optimisation of a series of benzoylpiperazines as Gly-T1 inhibitors for the treatment of schizophrenia culminating in the discovery of RG1678, the first potent and selective Gly-T1 inhibitor to demonstrate efficacy … Continue reading
Posted in Clinical Candidates, Transporter Modulator
Tagged CNS penetration, Gly-T1, hERG, Phase III, POC, PSA, RG1678, Roche, Schizophrenia, Transporters
Leave a comment
MedChemBuzz 